Eli Lilly and Company (NYSE: LLY) has revealed encouraging Phase 2 results for muvalaplin, an investigational once-daily oral inhibitor targeting lipoprotein(a) [Lp(a)], a hereditary risk factor for cardiovascular disease. The trial demonstrated that muvalaplin significantly lowered elevated Lp(a) levels, achieving…
Ipsen (Euronext: IPN; ADR: IPSEY) presented new data at the American Association for the Study of Liver Diseases (AASLD) from two Phase III open-label extension studies, evaluating the long-term efficacy and safety of Bylvay® in patients with Progressive Familial Intrahepatic…
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has provided an update regarding its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) for €11.00 per share in cash, valuing the transaction at approximately €2.0 billion. A presentation on Halozyme’s investor relations website outlines…
Brenus Pharma has announced the publication of a scientific article in Frontiers in Oncology detailing the results of its novel “off-the-shelf” cancer treatment. The company’s innovative platform replicates patients’ relapsing conditions in the lab to train the immune system to…
Care Access, a global clinical research company focused on advancing medicine, is hosting a Heart & Kidney Health Screening event in Houston, Texas. The initiative is designed to raise awareness about health risks, including lipoprotein(a) [Lp(a)], a harmful type of…
Tempus AI, Inc. (NASDAQ: TEM), a leader in utilizing AI to advance precision medicine and patient care, announced today that nine abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, taking place…
Gilead Sciences, Inc. (Nasdaq: GILD) has announced the upcoming presentation of over 40 HIV research studies at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), taking place from November 10-13. The research includes late-breaking findings, with…
BridgeBio Pharma, Inc. (Nasdaq: BBIO), an innovative biopharmaceutical company focused on treating genetic diseases, has announced the publication of a case study, “Applications of Portfolio Theory to Accelerating Biomedical Innovation,” in The Journal of Portfolio Management. This study, which highlights…
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) showcased findings from the long-term KINECT®-4 study, revealing that nearly 60% of participants achieved remission from tardive dyskinesia after 48 weeks of treatment with once-daily INGREZZA® (valbenazine) capsules. This research, titled “Remission of Tardive Dyskinesia…
A recent World Health Organization (WHO) study, published in eBioMedicine, has identified 17 priority pathogens that are endemic in various communities and urgently require new vaccines. This marks WHO’s first global effort to systematically prioritize endemic pathogens for vaccine development,…
Kashiv BioSciences, LLC, a globally integrated biopharmaceutical company, has appointed Dr. Sandeep Nilkanth Athalye as its new Global Chief Executive Officer. With over 20 years of experience in strategic and operational roles within the pharmaceutical industry, Dr. Athalye will lead…
Medidata, a brand of Dassault Systèmes and a leading provider of clinical trial solutions, has partnered with Cogstate, a leader in neuroscience solutions, to transform clinical trials and outcome measurements for central nervous system (CNS) diseases, including neurodegenerative, psychiatric, motor,…
